. "Jak optimalizovat l\u00E9\u010Dbu chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED farmakologickou modulac\u00ED srde\u010Dn\u00ED frekvence"@cs . "1"^^ . "How to optimise the treatment of chronic heart failure through pharmacological modulation of the heart rate"@en . . . "Jak optimalizovat l\u00E9\u010Dbu chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED farmakologickou modulac\u00ED srde\u010Dn\u00ED frekvence"@cs . . . "1"^^ . . "0862-8947" . . "Hradec, Jarom\u00EDr" . . "Klidov\u00E1 srde\u010Dn\u00ED frekvence (SF) je u nemocn\u00FDch s chronick\u00FDm srde\u010Dn\u00EDm selh\u00E1n\u00EDm v\u00FDznamn\u00FDm rizikov\u00FDm faktorem kardiovaskul\u00E1rn\u00ED mortality a morbidity. Farmakologick\u00E9 zpomalen\u00ED SF u t\u011Bchto nemocn\u00FDch v\u00FDznamn\u011B zlep\u0161uje jejich progn\u00F3zu. K dispozici je n\u011Bkolik l\u00E9\u010Div k farmakologick\u00E9mu zpomalen\u00ED SF, jejich m\u00EDsto v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED se sn\u00ED\u017Eenou ejek\u010Dn\u00ED frakc\u00ED definuj\u00ED sou\u010Dasn\u00E1 quidelines. Digoxin je ur\u010Den p\u0159edev\u0161\u00EDm ke kontrole komorov\u00E9 frekvence u nemocn\u00FDch se srde\u010Dn\u00EDm selh\u00E1n\u00EDm a tachyfibrilac\u00ED s\u00EDn\u00ED, v\u011Bt\u0161inou v kombinaci s betablok\u00E1tory, pokud nesta\u010D\u00ED monoterapie betablok\u00E1torem. \u00DAloha digoxinu p\u0159i srde\u010Dn\u00EDm selh\u00E1n\u00ED a sinusov\u00E9m rytmu je velmi sporn\u00E1. Betablok\u00E1tory jsou dnes spolu s inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE) u chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED l\u00E9ky prvn\u00ED volby. Sni\u017Euj\u00ED v\u00FDznamn\u011B mortalitu i morbiditu. Jejich p\u0159\u00EDzniv\u00FD \u00FA\u010Dinek je podm\u00EDn\u011Bn p\u0159edev\u0161\u00EDm zpomalen\u00EDm SF. U \u010D\u00E1sti nemocn\u00FDch z\u016Fst\u00E1v\u00E1 SF i p\u0159i l\u00E9\u010Db\u011B betablok\u00E1torem vy\u0161\u0161\u00ED ne\u017E 70/min. U t\u011Bchto nemocn\u00FDch lze vyu\u017E\u00EDt nov\u00FD bradykarduj\u00EDc\u00ED l\u00E9k ivabradin, bu\u010F v kombinaci s betablok\u00E1torem nebo p\u0159i jeho kontraindikaci. Dodate\u010Dn\u00E9 zpomalen\u00ED SF d\u00E1le zlep\u0161uje progn\u00F3zu nemocn\u00E9ho." . . "How to optimise the treatment of chronic heart failure through pharmacological modulation of the heart rate"@en . "6"^^ . . . "RIV/00064165:_____/13:10173192!RIV14-MZ0-00064165" . "23" . "RIV/00064165:_____/13:10173192" . . . . "2" . "CZ - \u010Cesk\u00E1 republika" . "Remedia" . "Klidov\u00E1 srde\u010Dn\u00ED frekvence (SF) je u nemocn\u00FDch s chronick\u00FDm srde\u010Dn\u00EDm selh\u00E1n\u00EDm v\u00FDznamn\u00FDm rizikov\u00FDm faktorem kardiovaskul\u00E1rn\u00ED mortality a morbidity. Farmakologick\u00E9 zpomalen\u00ED SF u t\u011Bchto nemocn\u00FDch v\u00FDznamn\u011B zlep\u0161uje jejich progn\u00F3zu. K dispozici je n\u011Bkolik l\u00E9\u010Div k farmakologick\u00E9mu zpomalen\u00ED SF, jejich m\u00EDsto v l\u00E9\u010Db\u011B chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED se sn\u00ED\u017Eenou ejek\u010Dn\u00ED frakc\u00ED definuj\u00ED sou\u010Dasn\u00E1 quidelines. Digoxin je ur\u010Den p\u0159edev\u0161\u00EDm ke kontrole komorov\u00E9 frekvence u nemocn\u00FDch se srde\u010Dn\u00EDm selh\u00E1n\u00EDm a tachyfibrilac\u00ED s\u00EDn\u00ED, v\u011Bt\u0161inou v kombinaci s betablok\u00E1tory, pokud nesta\u010D\u00ED monoterapie betablok\u00E1torem. \u00DAloha digoxinu p\u0159i srde\u010Dn\u00EDm selh\u00E1n\u00ED a sinusov\u00E9m rytmu je velmi sporn\u00E1. Betablok\u00E1tory jsou dnes spolu s inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu (ACE) u chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED l\u00E9ky prvn\u00ED volby. Sni\u017Euj\u00ED v\u00FDznamn\u011B mortalitu i morbiditu. Jejich p\u0159\u00EDzniv\u00FD \u00FA\u010Dinek je podm\u00EDn\u011Bn p\u0159edev\u0161\u00EDm zpomalen\u00EDm SF. U \u010D\u00E1sti nemocn\u00FDch z\u016Fst\u00E1v\u00E1 SF i p\u0159i l\u00E9\u010Db\u011B betablok\u00E1torem vy\u0161\u0161\u00ED ne\u017E 70/min. U t\u011Bchto nemocn\u00FDch lze vyu\u017E\u00EDt nov\u00FD bradykarduj\u00EDc\u00ED l\u00E9k ivabradin, bu\u010F v kombinaci s betablok\u00E1torem nebo p\u0159i jeho kontraindikaci. Dodate\u010Dn\u00E9 zpomalen\u00ED SF d\u00E1le zlep\u0161uje progn\u00F3zu nemocn\u00E9ho."@cs . "[B9B0C3615F0C]" . "heart rate; cardiovascular prognosis; ivabradine; digoxin; beta-blockers; Chronic heart failure"@en . "Jak optimalizovat l\u00E9\u010Dbu chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED farmakologickou modulac\u00ED srde\u010Dn\u00ED frekvence" . . "81475" . . . "Resting heart rate (HR) is a significant risk factor of cardiovascular mortality and morbidity in patients with chronic heart failure. Pharmacological slowing of the HR significantly improves prognosis in these patients. There are several drugs available for slowing the HR. Their role in the treatment of chronic heart failure with reduced ejection fraction is defined by specific quidelines. Digoxin is used especially for ventricular rate control in patients with heart failure and atrial tachyfibrillation, mostly in combination with a beta-blocker monotherapy is insufficient. The role of digoxin in heart failure and sinus rhythm is very controversial. Beta-blockers together with ACE (angiotensin converting enzyme) inhibitors are now the drugs of first choice in patients with chronic heart failure. They significantly decrease mortality as well as morbidity. Their beneficial effect is given mostly by HR slowing. Nevertheless, in some of these patients, the HR remains higher than 70/min despite beta-blocker therapy. In these patients, it is possible to use a new HR slowing drug, ivabradine, either in combination with a beta-blocker or as monotherapy if the beta-blocker is contraindicated. Additional HR slowing leads to further prowing leads to further prognostic improvement."@en . . "I" . "Jak optimalizovat l\u00E9\u010Dbu chronick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED farmakologickou modulac\u00ED srde\u010Dn\u00ED frekvence" .